Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH).

Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a comprehensive review of chromosomal abnormalities associated with drug sensitivity and resistance in hematological disorders. This work highlights the emergence of alteration-driven therapy, with certain agents (e.g., tyrosine kinase inhibitors, menin inhibitors, venetoclax) used across entities sharing common molecular lesions, while others remain disease-specific, such as in Helicobacter pylori-associated lymphomas.